The systemic administration of semi-synthetic EV-mimetics loaded with CRISPR/Cas9 targeting poly(ADP-ribose)polymerase 1 (PARP-1) demonstrably reduced the PARP-1 expression significantly in ovarian tumor tissue, thereby reducing the tumor progression [152]. Here, PARP1 is linked to neoplasm.